CareValidate, a compliance infrastructure company for telehealth brands, announced Thursday that it is launching an expanded menopause/perimenopause hormone replacement therapy pathway.
CareValidate helps digital health companies, retailers and wellness brands launch and scale virtual care. It offers a licensed provider network, pharmacy fulfillment and lab diagnostics. It supports programs for weight loss, longevity, dermatology, erectile dysfunction and more.
With the HRT pathway, CareValidate’s clients can launch hormone replacement offerings, including progesterone and estradiol, while relying on CareValidate’s provider network and pharmacy fulfillment. HRT is often used to treat menopause and replaces declining estrogen and progesterone levels.
“Importantly, menopause care isn’t a one-time prescription,” said Dr. Jiten Chhabra, co-founder and chief medical officer of CareValidate. “Women’s needs change over time, and CareValidate’s infrastructure is designed to support ongoing relationships, proactive follow-up, and treatment adjustments when clinically indicated. The objective is to make healthcare feel less like a series of disconnected transactions and more like having a dedicated care team looking after each patient.”
A major differentiator of the expanded offering is CareValidate’s AI-powered care agents, Chhabra said. These agents act as 24/7 personal healthcare concierges and help patients schedule appointments, keep medical records up to date, coordinate follow-ups and navigate care.
“Rather than requiring patients to manage every step themselves, the agents help anticipate their needs and ensure important aspects of their care don’t fall through the cracks, while clinical decisions remain with licensed healthcare professionals,” Chhabra stated.
Misinformation has historically led to a gap in access to HRT. A 2002 study on HRT falsely linked the medication to breast cancer. This study has since been debunked, and in 2025, the FDA announced that it is removing black box warning labels from menopausal HRT products.
However, women are still struggling to access the treatment they need for menopause. About 80% of women in menopause experience hot flashes or night sweats, according to the Menopause Society. A Mayo Clinic study estimates that menopause-related symptoms cost the U.S. about $1.8 billion in lost work time.
“Our overarching goal is to help more people access better healthcare, faster. In women’s health, that means enabling our partners to reach more patients, reduce unnecessary barriers to care, and support safe, evidence-based treatment over time,” Chhabra said. “We also want to raise the standard of care in cash-pay telehealth. Patients should expect the same commitment to clinical oversight, safety, privacy, and continuity of care whether they use insurance or pay directly.”
Photo: Toa55, Getty Images
